- Home
- ONFO vs VIRX Comparison
ONFO vs VIRX Comparison
Compare ONFO & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- VIRX
- Stock Information
- Founded
- ONFO 2018
- VIRX 2007
- Country
- ONFO United States
- VIRX United States
- Employees
- ONFO N/A
- VIRX N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- VIRX Health Care
- Exchange
- ONFO Nasdaq
- VIRX Nasdaq
- Market Cap
- ONFO 6.7M
- VIRX 7.0M
- IPO Year
- ONFO 2022
- VIRX N/A
- Fundamental
- Price
- ONFO $1.26
- VIRX $0.17
- Analyst Decision
- ONFO
- VIRX Buy
- Analyst Count
- ONFO 0
- VIRX 4
- Target Price
- ONFO N/A
- VIRX $5.00
- AVG Volume (30 Days)
- ONFO 158.2K
- VIRX 2.3M
- Earning Date
- ONFO 11-15-2024
- VIRX 03-06-2025
- Dividend Yield
- ONFO N/A
- VIRX N/A
- EPS Growth
- ONFO N/A
- VIRX N/A
- EPS
- ONFO N/A
- VIRX N/A
- Revenue
- ONFO $6,590,171.00
- VIRX N/A
- Revenue This Year
- ONFO $133.59
- VIRX N/A
- Revenue Next Year
- ONFO N/A
- VIRX N/A
- P/E Ratio
- ONFO N/A
- VIRX N/A
- Revenue Growth
- ONFO 29.25
- VIRX N/A
- 52 Week Low
- ONFO $0.39
- VIRX $0.13
- 52 Week High
- ONFO $1.88
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- ONFO 44.75
- VIRX 44.76
- Support Level
- ONFO $1.15
- VIRX $0.15
- Resistance Level
- ONFO $1.39
- VIRX $0.19
- Average True Range (ATR)
- ONFO 0.09
- VIRX 0.03
- MACD
- ONFO -0.01
- VIRX -0.00
- Stochastic Oscillator
- ONFO 36.67
- VIRX 21.00
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.